Coherus Oncology (CHRS) Other Non Operating Income (2013 - 2026)

Coherus Oncology has reported Other Non Operating Income for 14 years, with the latest figure at $1.4 million in Q1 2026.

• Quarterly Other Non Operating Income rose 649.73% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 109.48% YoY) and the FY2025 annual result came in at $1.6 million, up 112.45% from the prior year.
• Other Non Operating Income improved to $1.4 million in Q1 2026 per CHRS's latest filing, from -$3.7 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $2.9 million in Q2 2025 and troughed at -$19.0 million in Q4 2024.
• A 5-year average of -$1.0 million and a median of $1.4 million in 2022 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2023 and 2024: Other Non Operating Income soared 5300.0% in 2023, then plunged 14667.44% in 2024.
• Over 5 years, Other Non Operating Income stood at $1.3 million in 2022, then slumped by 109.63% to -$129000.0 in 2023, then slumped by 14667.44% to -$19.0 million in 2024, then jumped by 80.81% to -$3.7 million in 2025, then surged by 138.35% to $1.4 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $1.4 million, -$3.7 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.